Interstitial lung disease market presents new opportunities through 2026–2030

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Projected Increase In Market Value Of The Interstitial Lung Disease Market During 2026–2030?

The interstitial lung disease market size has demonstrated significant expansion in recent years. It is projected to grow from $2.09 billion in 2025 to $2.24 billion in 2026, at a compound annual growth rate (CAGR) of 7.2%. This historical growth can be attributed to the rising prevalence of chronic respiratory diseases, increased exposure to occupational and environmental pollutants, advancements in pulmonary imaging techniques, improved awareness of idiopathic pulmonary fibrosis, and the expansion of specialty pulmonary clinics.

The market for interstitial lung disease is projected to experience robust expansion over the coming years. This market is set to reach $3.09 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.4%. Factors contributing to this growth during the forecast period include an expanding elderly population, higher rates of interstitial lung disorder diagnoses, the greater uptake of targeted anti-fibrotic medications, an increase in research for new ILD treatments, and enhanced patient screening and monitoring initiatives. Key trends anticipated for the forecast period encompass a heightened focus on early and precise ILD diagnosis, broader use of anti-fibrotic therapies, an increased commitment to managing disease progression, the development of multidisciplinary care strategies, and better availability of long-term ILD treatment.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/interstitial-lung-disease-global-market-report

What Major Factors Are Driving The Interstitial Lung Disease Market Forward?

The increasing occurrence of autoimmune conditions is anticipated to boost the expansion of the interstitial lung disease market in the future. Autoimmune conditions are defined as health issues where the immune system mistakenly targets the body’s own healthy tissues and cells. An elevated prevalence of autoimmune disorders influences the interstitial lung disease market by stimulating the need for healthcare services related to ILD, fostering research and development efforts, and pushing innovations in treatments and patient management. For example, data from September 2023, provided by the Institute for Health Metrics and Evaluation, a US-based global health research center, projects that worldwide cases of rheumatoid arthritis are estimated to climb to 31.7 million by the year 2050, demonstrating a notable increase during this timeframe. Consequently, the growing frequency of autoimmune diseases is fueling the development of the interstitial lung disease market.

How Are Segments Identified Within The Interstitial Lung Disease Market Segment Framework?

The interstitial lung disease market covered in this report is segmented –

1) By Drug Type: Oral Corticosteroids, Immune Suppressing, Anti-Fibrotic Medication, Other Drugs

2) By Disease Type: Interstitial Pneumonia, Idiopathic Pulmonary Fibrosis, Nonspecific Interstitial Pneumonitis, Hypersensitivity Pneumonitis, Cryptogenic Organizing Pneumonia (COP), Sarcoidosis, Acute Interstitial Pneumonitis

3) By Application: Adults, Children

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Oral Corticosteroids: Prednisone, Methylprednisolone, Dexamethasone

2) By Immune Suppressing: Azathioprine, Methotrexate, Mycophenolate Mofetil

3) By Anti-Fibrotic Medication: Pirfenidone, Nintedanib

4) By Other Drugs: Antioxidants, Anticoagulants, Other Novel Therapies

Which Trends Are Impacting The Progress Of The Interstitial Lung Disease Market?

Companies operating within the interstitial lung disease market are increasingly concentrating on introducing new products, particularly groundbreaking therapies for a range of interstitial lung conditions like idiopathic pulmonary fibrosis (IPF). Idiopathic pulmonary fibrosis (IPF) stands as a chronic, progressive lung condition, characterized by the scarring of lung tissue, which leads to difficulties in breathing and impaired oxygen transfer. As an illustration, in February 2024, C.H. Boehringer Sohn AG & Co. KG, a biopharmaceutical company from Germany, obtained FDA approval for its BI 1015550 Therapy, designed for the management of Idiopathic Pulmonary Fibrosis. BI 1015550 is an investigational oral treatment that acts by inhibiting phosphodiesterase 4B (PDE4B), providing both antifibrotic and anti-inflammatory properties aimed at decelerating the decline of lung function in idiopathic pulmonary fibrosis (IPF).

Who Are The Companies Competing Within The Interstitial Lung Disease Market?

Major companies operating in the interstitial lung disease market are Roche Laboratories Inc., Merck & Co. Inc., Bayer AG, Novartis Pharmaceuticals Corporation, The Bristol-Myers Squibb Company, Amgen Inc., Boehringer Ingelheim, Teva Pharmaceuticals USA Inc., AstraZeneca plc, Horizon Pharma USA Inc., Genentech Inc., Amneal Pharmaceuticals LLC, Insmed Inc., EmphyCorp Inc., Verseau Therapeutics, Regend Therapeutics Co., LTT Bio-Pharma Co. Ltd., Galecto Biotech, Pulmatrix Inc., PureTech Health plc, Pneuma Respiratory Inc., Bellerophon Therapeutics Inc., MediciNova Inc., Altavant Sciences Inc., Verona Pharma plc

Get The Full Interstitial Lung Disease Market Report:

https://www.thebusinessresearchcompany.com/report/interstitial-lung-disease-global-market-report

Which Region Is The Top Contributor To The Interstitial Lung Disease Market By Share?

North America was the largest region in the interstitial lung disease market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the interstitial lung disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Interstitial Lung Disease Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/interstitial-lung-disease-global-market-report

Browse Through More Reports Similar to the Global Interstitial Lung Disease Market 2026, By The Business Research Company

Artificial Lung Market Report 2026

https://www.thebusinessresearchcompany.com/report/artificial-lung-global-market-report

Black Lung Disease Market Report 2026

https://www.thebusinessresearchcompany.com/report/black-lung-disease-global-market-report

Idiopathic Pulmonary Fibrosis Market Report 2026

https://www.thebusinessresearchcompany.com/report/idiopathic-pulmonary-fibrosis-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795